Strs Ohio Buys New Stake in Synthorx Inc (THOR)
Strs Ohio bought a new stake in Synthorx Inc (NASDAQ:THOR) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 1,900 shares of the medical instruments supplier’s stock, valued at approximately $38,000.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Matisse Capital bought a new stake in shares of Synthorx during the 4th quarter valued at about $956,000. Dean Capital Investments Management LLC bought a new stake in shares of Synthorx during the 4th quarter valued at about $827,000. Monashee Investment Management LLC bought a new stake in shares of Synthorx during the 4th quarter valued at about $435,000. Orbimed Advisors LLC bought a new stake in shares of Synthorx during the 4th quarter valued at about $92,398,000. Finally, RA Capital Management LLC bought a new stake in shares of Synthorx during the 4th quarter valued at about $169,014,000. 64.65% of the stock is currently owned by institutional investors.
A number of brokerages have recently issued reports on THOR. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Synthorx in a research report on Wednesday, May 1st. Svb Leerink reiterated an “outperform” rating on shares of Synthorx in a research report on Monday, March 18th. Zacks Investment Research downgraded Synthorx from a “buy” rating to a “hold” rating in a research report on Tuesday, March 19th. Finally, Leerink Swann started coverage on Synthorx in a report on Friday, March 15th. They set an “outperform” rating on the stock. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $23.67.
Synthorx (NASDAQ:THOR) last announced its quarterly earnings data on Tuesday, April 30th. The medical instruments supplier reported ($0.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.03). As a group, research analysts anticipate that Synthorx Inc will post -1.65 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Strs Ohio Buys New Stake in Synthorx Inc (THOR)” was first posted by Marea Informative and is the sole property of of Marea Informative. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.mareainformativa.com/news/2019/05/16/strs-ohio-buys-new-stake-in-synthorx-inc-thor.html.
Synthorx, Inc, a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor.
Featured Story: Fundamental Analysis and Choosing Stocks
Want to see what other hedge funds are holding THOR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Synthorx Inc (NASDAQ:THOR).
Receive News & Ratings for Synthorx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthorx and related companies with MarketBeat.com's FREE daily email newsletter.